These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 7073946)
21. Biotransformation and in vitro activity of an arabinosylcytosine 5'-chloro-5'-deoxy analog. Novotný L; Reichelová V; Balázová E; Scheithauer W; Benesová M; Ujházy V Anticancer Drugs; 1991 Oct; 2(5):495-502. PubMed ID: 1804392 [TBL] [Abstract][Full Text] [Related]
22. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. Abe I; Saito S; Hori K; Suzuki M; Sato H Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175 [TBL] [Abstract][Full Text] [Related]
23. Mechanisms of delivery of liposome-encapsulated cytosine arabinoside to CV-1 cells in vitro. Fluorescence-microscopic and cytotoxicity studies. Brown PM; Silvius JR Biochim Biophys Acta; 1990 Apr; 1023(3):341-51. PubMed ID: 2110480 [TBL] [Abstract][Full Text] [Related]
24. Approaches to overcome in vivo anti-cancer drug resistance. Rustum YM; Radel S; Campbell J; Mayhew E Prog Clin Biol Res; 1986; 223():187-202. PubMed ID: 3492716 [TBL] [Abstract][Full Text] [Related]
25. Transport and metabolism of 1-beta-D-arabinofuranosylcytosine in human ovarian adenocarcinoma cells. Jamieson GP; Snook MB; Bradley TR; Bertoncello I; Wiley JS Cancer Res; 1989 Jan; 49(2):309-13. PubMed ID: 2910450 [TBL] [Abstract][Full Text] [Related]
26. Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts. Jamieson GP; Finch LR; Snook M; Wiley JS Cancer Res; 1987 Jun; 47(12):3130-5. PubMed ID: 3472653 [TBL] [Abstract][Full Text] [Related]
27. Analysis of the drug synergism between thymidine and arabinosyl cytosine using mouse S49 T lymphoma mutants. Cohen A; Ullman B Cancer Chemother Pharmacol; 1985; 14(1):70-3. PubMed ID: 3965162 [TBL] [Abstract][Full Text] [Related]
28. Potentiation of the bleomycin, arabinofuranosylcytosine and adriamycin-caused inhibition of DNA synthesis in lymphocytes by bestatin in vitro. Leyhausen G; Schröder HC; Schuster DK; Maidhof A; Umezawa H; Müller WE Eur J Cancer Clin Oncol; 1985 Nov; 21(11):1325-30. PubMed ID: 2416570 [TBL] [Abstract][Full Text] [Related]
29. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines. Ramilo-Torno LV; Avramis VI Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176 [TBL] [Abstract][Full Text] [Related]
30. Target-sensitive immunoliposomes as an efficient drug carrier for antiviral activity. Ho RJ; Rouse BT; Huang L J Biol Chem; 1987 Oct; 262(29):13973-8. PubMed ID: 2820987 [TBL] [Abstract][Full Text] [Related]
31. Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. Sarkar M; Han T; Damaraju V; Carpenter P; Cass CE; Agarwal RP Biochem Pharmacol; 2005 Aug; 70(3):426-32. PubMed ID: 15950950 [TBL] [Abstract][Full Text] [Related]
32. Cytosine arabinoside in the treatment of T-cell acute lymphoblastic leukemia. Wiley JS; Woodruff RK; Jamieson GP; Firkin FC; Sawyer WH Aust N Z J Med; 1987 Aug; 17(4):379-86. PubMed ID: 3501710 [TBL] [Abstract][Full Text] [Related]
33. Application of an in vitro system in the study of chemotherapeutic drug effects on DNA replication. Diaz-Perez MJ; Wainer IW; Zannis-Hadjopoulos M; Price GB J Cell Biochem; 1996 Jun; 61(3):444-51. PubMed ID: 8761948 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of DNA synthesis by cytosine arabinoside: relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease. Preisler HD; Epstein J; Raza A; Azarnia N; Browman G; Booker L; Goldberg J; Gottlieb A; Brennan J; Grunwald H Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1061-8. PubMed ID: 6540689 [TBL] [Abstract][Full Text] [Related]
35. 1-beta-D-arabinofuranosylcytosine nucleotide inhibition of sialic acid metabolism in WI-38 cells. Myers-Robfogel MW; Spataro AC Cancer Res; 1980 Jun; 40(6):1940-3. PubMed ID: 7371029 [TBL] [Abstract][Full Text] [Related]
36. Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. Boyer SH; Sun Z; Jiang H; Esterbrook J; Gómez-Galeno JE; Craigo W; Reddy KR; Ugarkar BG; MacKenna DA; Erion MD J Med Chem; 2006 Dec; 49(26):7711-20. PubMed ID: 17181153 [TBL] [Abstract][Full Text] [Related]
37. Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine. Horber DH; Schott H; Schwendener RA Br J Cancer; 1995 May; 71(5):957-62. PubMed ID: 7734320 [TBL] [Abstract][Full Text] [Related]
38. Cytosine-arabinoside does not inhibit incorporation of 3H-thymidine in herpes simplex virus transformed cells. Roubal J Arch Virol; 1977; 53(3):255-9. PubMed ID: 193465 [No Abstract] [Full Text] [Related]
39. Altered sensitivity to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate of DNA polymerase alpha from leukemic blasts of acute lymphoblastic leukemia. TAnaka M; Yoshida S Cancer Res; 1982 Feb; 42(2):649-53. PubMed ID: 6948608 [TBL] [Abstract][Full Text] [Related]
40. Effects of 1-beta-D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution. Ross DD; Chen SR; Cuddy DP Cancer Res; 1990 May; 50(9):2658-66. PubMed ID: 2328491 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]